Danone has struck a deal to acquire a majority stake in Kate Farms, a US-based business that makes plant-based and organic nutrition products. Founded in 2011 by Richard and Michelle Laver, California-based Kate Farms supplies a range of products from nutritional shakes on sale at mass-market retailers to tube-feeding products sold directly to healthcare providers. Kate Farms categorises its product into four areas: “everyday nutrition” for daily dietary needs; “medical nutrition” for medical and dietary requirements; “kids nutrition” for children aged one to 13 years; and specialised nutrition to support diets targeting specific health conditions. The company's customers span retailers including Walmart and Amazon to more than 1,400 hospitals. Danone Group deputy CEO Shane Grant said: “This partnership aligns perfectly with our science-based and patient-centred approach to specialised nutrition. “Kate Farms’ innovative medical nutrition products expand our offerings, enhance our ability to provide better solutions for people with wide-ranging health needs, and support healthier lives, both in the US and globally.” The financial details of the agreement have not been disclosed. Danone said the senior management of Kate Farms will retain a minority stake in the business. Kate Farms CEO Brett Matthews will assume the role of chairman and CEO of Danone’s North American Medical Nutrition division. Matthews said: “Together, we can bring our innovative scientifically developed nutritional products to more and more people. “Building on Danone’s expertise, we can also expand internationally. It is rare that two companies come together by virtue of the same values and a philosophy of building a growth company that helps people live their best lives, delivered by team members who show their heart and expertise every day.” Commenting on the deal, Barclays equity analyst Warren Ackerman, said: “Whilst the deal is not material for Danone, we consider it a clear signal as to the company's direction of travel and it follows a similar path to the Functional Formularies deal.” In May last year, Danone snapped up US tube-feeding business Functional Formularies from private-equity firm Swander Pace Capital. Ackerman said Barclays estimates Danone's adult medical nutrition business accounts for 12% of the company's revenues and close to 20% of group EBIT. The business is, he added, "a good hedge to declining fertility rates which could impact its infant nutrition unit". Danone has three group divisions: Essential Dairy & Plant-Based Products; Waters; and Specialized Nutrition. The medical business is housed within Specialized Nutrition, alongside infant formula. Story Continues In 2024, the group’s sales grew by 4.3% on a like-for-like basis, reaching €27.37bn. The Specialized Nutrition segment saw sales increase by 5.1% on a reported basis to €8.93bn. Danone does not provide a breakdown of its medical-nutrition sales but said the growth its Specialized Nutrition division saw in 2024 in North America was led by the unit. Meanwhile, it reported “strong momentum” for medical nutrition across its China, north Asia and Oceania reporting unit last year. "Danone buys majority of plant-based nutrition business Kate Farms" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Danone buys majority of plant-based nutrition business Kate Farms
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...